Hedge Fund Long Positions in U.S. Healthcare Stocks Near Five-Year High
N.R. Finch
Goldman Sachs reports hedge fund long exposure to US healthcare has reached a near-five-year high, with buying concentrated in devices, life-science tools, and pharma; AI drug discovery, a surging M&A cycle, and faster FDA approvals are pulling capital in — but crowding risk is building in parallel.
How large is the positioning?
Per Goldman's July 24 client note, hedge fund long exposure to US healthcare approached a five-year high last week — the second consecutive week of net buying.
Buying clustered in three sub-sectors: medical devices & supplies, life-science tools, and pharmaceuticals.
Out of roughly $1 trillion in equity hedge fund assets, healthcare-focused funds manage about $283 billion. This means → more than one in every four dollars is parked in healthcare.
What is driving capital into healthcare?
Catalyst one: AI is speeding up drug R&D. A prior Goldman report noted that AI applications in drug discovery are lifting research efficiency and compressing the lab-to-clinic timeline.
Catalyst two: M&A is surging. Pharma M&A deal volume is projected at $173 billion in 2026 — the highest since 2019. In plain terms = big pharma has cash and is willing to pay up for smaller companies' pipelines.
Catalyst three: faster approvals. The FDA approved more new drugs last year than in any year since 2020, accelerating the pace at which new therapies hit the market and lifting valuation expectations.
What has changed inside M&A deals?
Trium Capital hedge fund manager Felix Lo noted that volatility in the drug-approval regulatory process has risen this year.
Yet in acquisitions, smaller target companies are more willing to accept steeper discounts in exchange for cash certainty.
This means → buyers are getting better prices and deals are easier to close. Lo called it "an active environment for transactions."
How strong are healthcare fund returns?
Dedicated healthcare hedge funds posted returns near 40% from August 2025 through April 2026; diversified equity hedge funds returned 17% over the same period.
Put simply = betting on healthcare earned more than double what a broad equity hedge fund made.
The performance is attracting new capital: 24% of funds launched this year focus on healthcare — the highest share since at least 2009.
How serious is the crowding risk?
HFR data show total hedge fund industry assets grew by a record $409.3 billion in Q2, lifting total AUM to $5.6 trillion.
New funds continue to pile into healthcare, and sector positioning is getting increasingly crowded.
This reflects a classic tension: the stronger the catalysts and the more concentrated the capital, the greater the stampede risk if the wind shifts — historically, crowded trades unwind faster than they build.
Content is for reference only, not financial advice.